Skip to main content

Advertisement

SpringerLink
Log in

Combating diabetic nephropathy with drug therapy

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Diabetes mellitus is the leading cause of end-stage renal disease and also increases the risk of atherosclerotic vascular disease. Hypertension amplifies both problems. Detection of microalbuminuria, a common and early manifestation of diabetic nephropathy and a marker for cardiovascular risk, permits early treatment to reduce progression of nephropathy and vascular disease in diabetes. Although optimal glycemic control is essential to reduce the risk of nephropathy, aggressive blood pressure lowering to a level of 130/80 mg Hg or below in hypertensive diabetic patients is as important as glycemic control. Initial drug therapy for nephropathy should include an angiotensin-converting enzyme inhibitor (or if contraindicated, an angiotensin receptor blocker), as several large randomized double-blinded multicenter clinical trials have demonstrated an independent renoprotective effect with renin angiotensin system inhibition.

The role of advanced glycation end products in the pathogenesis of renal and vascular disease in diabetes is becoming more clearly established. However, the use of therapeutic strategies directed at blocking their effect still awaits further investigation. A multifaceted intervention program that combines optimal glycemic control, lifestyle modification/cardiovascular prevention guidelines such as lipid control and smoking cessation, with appropriate antihypertensive therapy when indicated, will prevent or delay both the occurrence and progression of diabetic nephropathy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Harris MI, Flegal KM, Cowie CC, et al.: Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care 1998, 21:518–524.

    Article  PubMed  CAS  Google Scholar 

  2. Bakris GL, Williams M, Dworkin L, et al. for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group: Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000, 36:646–661. A concise review of the literature that provides the practicing physician treatment recommendations for hypertension in patients with diabetes that are based on the results of large-scale randomized clinical trials.

    PubMed  CAS  Google Scholar 

  3. US Renal Data System: USRDS 2000 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive Kidney Diseases; April 2000.

  4. Mogensen CE, Hansen KW, Pedersen MM, Christensen CK: Renal factors influencing blood pressure threshold and choice of treatment for hypertension in IDDM. Diabetes Care 1991, 14(suppl 4):13–26.

    PubMed  Google Scholar 

  5. Olivarius N de F, Andreasen AH, Keiding N, Mogensen CE: Epidemiology of renal involvement in newly-diagnosed middle-aged and elderly diabetic patients: cross-sectional data from the population-based study. Diabetologia 1993, 36:1007–1016.

    Article  Google Scholar 

  6. Ravid M, Brosh D, Ravid-Safran D, et al.: Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 1998, 11:998–1004.

    Article  Google Scholar 

  7. Cowie CC, Port FK, Wolfe RA, et al.: Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med 1989, 321:1074–1079.

    Article  PubMed  CAS  Google Scholar 

  8. Breyer J: Diabetic nephropathy. In Primer on Kidney Disease, edn 2. Edited by Greenberg A. San Diego, CA: Harcourt Brace and Company; 1998:215–220.

    Google Scholar 

  9. Ljungman S, Wikstrand J, Hartford M, Berglund G: Urinary albumin excretion-a predictor of risk of cardiovascular disease. A prospective 10-year follow-up of middle-aged nondiabetic normal and hypertensive men. Am J Hypertens 1996, 9:770–778.

    Article  PubMed  CAS  Google Scholar 

  10. Tuttle KR, Puhlman ME, Cooney SK, Short R: Urinary albumin and insulin as predictors of coronary artery disease: an angiographic study. Am J Kidney Dis 1999, 34:918–925.

    PubMed  CAS  Google Scholar 

  11. Keane WF, Eknoyan G: Proteinuria, albuminuria, risk assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999, 33:1004–1010.

    PubMed  CAS  Google Scholar 

  12. The Diabetes Control and Complications Research Group: Effect of intensive therapy on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977–986.

    Article  Google Scholar 

  13. The Diabetes Control and Complications Research Group: Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995, 7:1703–1720.

    Google Scholar 

  14. Stratton IM, Adler AI, Neil HA, et al.: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405–412.

    Article  PubMed  CAS  Google Scholar 

  15. Levey AS, Beto JA, Coronado BE, et al.: Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998, 32:853–906.

    PubMed  CAS  Google Scholar 

  16. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703–713. The UKPDS found a decrease in diabetes-related events (24%) and microvascular end points (37%) among 758 patients in the tight blood pressure group compared to 390 patients in the less tight blood pressure control (144/82 mm Hg vs 154/87 mm Hg). There was no difference in either microvascular or macrovascular outcomes among subjects in the tight blood pressure group randomized to receive either atenolol or captopril.

    Google Scholar 

  17. Egger M, Davey Smith G, Stettler C, Diem P: Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: a meta-analysis. Diabet Med 1997, 14:919–928.

    Article  PubMed  CAS  Google Scholar 

  18. The sixth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC VI) [no authors listed]. Arch Intern Med 1997, 154:2413–2446.

  19. Lazarus JM, Bourgoignie JJ, Buckalew VM, et al.: Achievement and safety of a low BP goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension 1997, 29:641–650.

    PubMed  CAS  Google Scholar 

  20. Mogensen CE: The kidney in diabetes: how to control renal and related cardiovascular complications. Am J Kidney Dis 2001, 37(suppl 2):S2-S6.

    PubMed  CAS  Google Scholar 

  21. Defronzo RA: Pharmacologic therapy for type II diabetes mellitus. Ann Intern Med 1999, 131:281–303.

    PubMed  CAS  Google Scholar 

  22. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensin-convertingenzyme inhibition on diabetic nephropathy. N Engl J Med 1993, 329:1456–1462.

    Article  PubMed  CAS  Google Scholar 

  23. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253–259. A large randomized multicenter trial with over 3500 people with diabetes and at least one other cardiovascular risk factor, who were assigned to ramipril or placebo and were followed for 4.5 years, with renal disease as the primary outcome. The ramipril group benefited from a 24% risk reduction for developing overt nephropathy, an effect reported to be independent of blood pressure reduction.

    Article  Google Scholar 

  24. Jerums G, Allen TJ, Campbell DJ, on behalf of the Melbourne Diabetic Nephropathy Study Group: Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis 2001, 37:890–899. This study reported that the ACE inhibitor was more effective than the dihydropyridine CCB or placebo in reducing urinary albumin excretion and the progression of nephropathy among 33 type 1 normotensive diabetic patients followed over 3 years with low-dose therapy aimed at reducing diastolic blood pressure by 5 mm Hg.

    PubMed  CAS  Google Scholar 

  25. The ACE Inhibitors in Diabetic Nephropathy Trialist Group: Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001, 134:370–379.

    Google Scholar 

  26. Bakris GL, Weir MR: ACE inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000, 160:685–693.

    Article  PubMed  CAS  Google Scholar 

  27. Agodoa LY, Appel L, Bakris GL, et al.: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephro sclerosis: a randomized controlled trial. JAMA 2001, 285:2719–2728.

    Article  PubMed  CAS  Google Scholar 

  28. Pitt B, Segal R, Martinez FA, et al.: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997, 49:747–752.

    Article  Google Scholar 

  29. Muirhead N, Feagan BF, Mahon J, et al.: The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial. Curr Ther Res 1999, 60:650–660.

    Article  CAS  Google Scholar 

  30. Lievre M, Gueyffier F, Ekbom T, for the INDIANA Steering Committee: Efficacy of diuretics and beta blockers in diabetic hypertensive patients. Diabetes Care 2000, 23(suppl 2):B65-B71.

    PubMed  Google Scholar 

  31. Gress TW, Nieto FJ, Shahar E, for the Atherosclerosis Risk in Communities Study: Hypertension and antihypertensive therapy and the risk factors for the type 2 diabetes mellitus. N Engl J Med 2000, 342:905–912.

    Article  PubMed  CAS  Google Scholar 

  32. Giugliano D, Acampora R, Marfella R, et al.: Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulindependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997, 126:955–959.

    PubMed  CAS  Google Scholar 

  33. Ritz E, Orth SR: Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999, 341:1127–1133.

    Article  PubMed  CAS  Google Scholar 

  34. Locatelli F, DelVecchio L, Marai P, Colzani S: The renoprotective effect of antihypertensive drugs. J Nephrol 1998, 11:330–336.

    PubMed  CAS  Google Scholar 

  35. Tatti P, Pahor M, Byington RP, et al.: Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998, 21:597–610.

    Article  PubMed  CAS  Google Scholar 

  36. Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. The HOT Study Group. Lancet 1998, 351:1755–1762.

    Article  PubMed  CAS  Google Scholar 

  37. Tuomilehto J, Rastenyte D, Birkenhager WH, et al.: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999, 340:677–684.

    Article  PubMed  CAS  Google Scholar 

  38. Estacio RO, Barrett JW, Hiatt WR, et al.: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998, 338:645–652.

    Article  PubMed  CAS  Google Scholar 

  39. Rachmani R, Levi Z, Slavachovsky I, et al.: Effect of an alphaadrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study. Nephron 1998, 80:175–182.

    Article  PubMed  CAS  Google Scholar 

  40. ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000, 283:1967–1975.

    Article  Google Scholar 

  41. Bakris GL, Weir MR, DeQuattro V, McMahon FG: Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998, 54:1283–1289.

    Article  PubMed  CAS  Google Scholar 

  42. Belz GG, Breithaupt K, Erb K, et al.: Influence of the angiotensin converting enzyme inhibitor cilazapril, the betablocker propranolol and their combination on haemodynamics in hypertension. J Hypertens 1989, 7:817–824.

    Article  PubMed  CAS  Google Scholar 

  43. Imani F, Horii Y, Suthanthiran M, et al.: Advanced glycosylation end product-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon gamma: Role in tissue remodeling. J Exp Med 1993, 178:2165–2172.

    Article  PubMed  CAS  Google Scholar 

  44. Hangaishi M, Taguchi J, Miyata T, et al.: Increased aggregation of human platelets produced by advanced glycation end products in vitro. Biochem Biophys Res Commun 1998, 248:285–292.

    Article  PubMed  CAS  Google Scholar 

  45. Sabbatini M, Sansone G, Uccello F, et al.: Early glycosylation products in-duce glomerular hyperfiltration in normal rats. Kidney Int 1992, 42:875–881.

    PubMed  CAS  Google Scholar 

  46. McVerry BA, Hopp AF, Huehns RR: Production of pseudodiabetic renal glomerular changes in mice after repeated injections of glycosylated proteins. Lancet 1980, 1:738–740.

    Article  PubMed  CAS  Google Scholar 

  47. Brownlee M, Vlassara H, Kooney A, et al.: Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986, 232:1629–1632.

    Article  PubMed  CAS  Google Scholar 

  48. Vasan S, Zhang X, Kapurniotu A, et al.: An agent cleaving glucose- derived protein cross-links in vitro and in vivo. Nature 1996, 382:275–278.

    Article  PubMed  CAS  Google Scholar 

  49. Nakamura S, Makita Z, Ishikawa S, et al.: Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 1997, 46:895–899.

    Article  PubMed  CAS  Google Scholar 

  50. Rachmani R, Ravid M: Risk factors for nephropathy in type 2 diabetes mellitus. Compr Ther 1999, 25:366–369.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, King Drew Medical Center, 12021 South Wilmington Avenue, 90059, Los Angeles, CA, USA

    David Martins MD & Keith Norris MD

Authors
  1. David Martins MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keith Norris MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martins, D., Norris, K. Combating diabetic nephropathy with drug therapy. Curr Diab Rep 1, 148–156 (2001). https://doi.org/10.1007/s11892-001-0027-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-001-0027-5

Keywords

Search

Navigation